Skip to main content
. 2022 Feb 14;8(1):veac010. doi: 10.1093/ve/veac010

Figure 5.

Figure 5.

Neutralization efficacy and growth kinetics of three B.1.1.7 variants. (A) Further mutant accumulations of D138Y and A701V in the spike protein were detected within the SARS-CoV-2 B.1.1.7_S sub-lineage. (B&C) Functional evaluation of virus isolates from the three B.1.1.7 variants: the originally defined B.1.1.7 (B.1.1.7_O), B.1.1.7_S, and B.1.1.7_S sub-lineage carrying two extra spike mutations D138Y and A701V (B.1.1.7_S+). (B) Neutralization efficacy of sera from fully vaccinated individuals (n = 7, BNT162b2) against active virus of the three B.1.1.7 variants. ID50, the serum dilution required for 50 per cent virus inhibition. Bars represent the median ID50 values with 95 per cent confidence interval. *P < 0.05; Wilcoxon matched-pairs signed rank test, ns not significant. (C). Growth kinetics of B.1.1.7_O, B.1.1.7_S, and B.1.1.7_S+ on Calu 3 cells as titrated by plaque assay. All data represent three independent experiments, each with two technical replicates.